114 related articles for article (PubMed ID: 25430851)
1. MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors.
Chio II; Yordanov G; Tuveson D
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25430851
[No Abstract] [Full Text] [Related]
2. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
3. Concepts to Target MYC in Pancreatic Cancer.
Wirth M; Mahboobi S; Krämer OH; Schneider G
Mol Cancer Ther; 2016 Aug; 15(8):1792-8. PubMed ID: 27406986
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma.
Zhang M; Fan HY; Li SC
Biomed Pharmacother; 2015 Jul; 73():123-8. PubMed ID: 26211592
[TBL] [Abstract][Full Text] [Related]
5. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
6. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
7. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
9. Mouse Models of Pancreatic Ductal Adenocarcinoma.
Ponz-Sarvise M; Tuveson DA; Yu KH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
[TBL] [Abstract][Full Text] [Related]
10. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
[TBL] [Abstract][Full Text] [Related]
11. Clinical study of genomic drivers in pancreatic ductal adenocarcinoma.
Barrett MT; Deiotte R; Lenkiewicz E; Malasi S; Holley T; Evers L; Posner RG; Jones T; Han H; Sausen M; Velculescu VE; Drebin J; O'Dwyer P; Jameson G; Ramanathan RK; Von Hoff DD
Br J Cancer; 2017 Aug; 117(4):572-582. PubMed ID: 28720843
[TBL] [Abstract][Full Text] [Related]
12. Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
Gore J; Imasuen-Williams IE; Conteh AM; Craven KE; Cheng M; Korc M
Cancer Lett; 2016 Aug; 379(1):143-53. PubMed ID: 27267807
[TBL] [Abstract][Full Text] [Related]
13. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
Rabi T; Catapano CV
Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
[TBL] [Abstract][Full Text] [Related]
14. Use of predictive markers in oncology: are phase 3 trials always required?
Markman M
Oncology; 2011; 81(1):1-2. PubMed ID: 21894048
[No Abstract] [Full Text] [Related]
15. Pancreatic cancer in 2017: Rebooting pancreatic cancer knowledge and treatment options.
Semaan A; Maitra A
Nat Rev Gastroenterol Hepatol; 2018 Feb; 15(2):76-78. PubMed ID: 29317774
[No Abstract] [Full Text] [Related]
16. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
17. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase 2 Facilitates Pancreatic Cancer Growth and Metastasis by Stimulating GLUT1-Mediated Glucose Transport.
Nagarajan A; Dogra SK; Sun L; Gandotra N; Ho T; Cai G; Cline G; Kumar P; Cowles RA; Wajapeyee N
Mol Cell; 2017 Aug; 67(4):685-701.e6. PubMed ID: 28803777
[TBL] [Abstract][Full Text] [Related]
19. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
